Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Potter

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Plos One|December 22, 2006
Development of a tumor-selective approach to treat metastatic cancerKaren S Aboody, Rebecca A Bush, Elizabeth Garcia, et al.
Bioorganic & Medicinal Chemistry|November 25, 2017
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitorsWilliam R Shadrick, Peter J Slavish, Sergio C Chai, et al.
Plos One|March 30, 2011
Nerve agent hydrolysis activity designed into a human drug metabolism enzymeAndrew C Hemmert, Tamara C Otto, Roberto A Chica, et al.
Nature Medicine|March 6, 2019
Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomasScott Newman, Liying Fan, Allison Pribnow, et al.
Cell Reports|December 2, 2014
Targeting the DNA repair pathway in Ewing sarcomaElizabeth Stewart, Ross Goshorn, Cori Bradley, et al.
Cancer Research|July 12, 2020
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP Jake Slavish, Liying Chi, Mi-Kyung Yun, et al.
Cancer Cell|December 17, 2013
Targeting oxidative stress in embryonal rhabdomyosarcomaXiang Chen, Elizabeth Stewart, Anang A Shelat, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Plos One|December 22, 2006
Development of a tumor-selective approach to treat metastatic cancerKaren S Aboody, Rebecca A Bush, Elizabeth Garcia, et al.
Bioorganic & Medicinal Chemistry|November 25, 2017
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitorsWilliam R Shadrick, Peter J Slavish, Sergio C Chai, et al.
Plos One|March 30, 2011
Nerve agent hydrolysis activity designed into a human drug metabolism enzymeAndrew C Hemmert, Tamara C Otto, Roberto A Chica, et al.
Nature Medicine|March 6, 2019
Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomasScott Newman, Liying Fan, Allison Pribnow, et al.
Cell Reports|December 2, 2014
Targeting the DNA repair pathway in Ewing sarcomaElizabeth Stewart, Ross Goshorn, Cori Bradley, et al.
Cancer Research|July 12, 2020
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP Jake Slavish, Liying Chi, Mi-Kyung Yun, et al.
Cancer Cell|December 17, 2013
Targeting oxidative stress in embryonal rhabdomyosarcomaXiang Chen, Elizabeth Stewart, Anang A Shelat, et al.
Pageof 9